The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China.
Department of Medical Oncology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
Cancer Med. 2023 Mar;12(5):5649-5655. doi: 10.1002/cam4.5357. Epub 2022 Nov 16.
Immunotherapy has exhibited efficacy in thymic carcinoma patients; however, there are insufficient data to confirm this efficacy in thymoma. The toxicity of immunotherapy also remains to be determined.
The efficacy and safety of immunotherapy were analyzed in 11 thymoma patients who received PD-1 inhibitors according to a range of relevant indexes including the objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and immunotherapy-related adverse events.
The PFS and OS rates for all patients were 12.8 and 56.5 months, respectively. No difference in efficacy was detected between monotherapy and combination therapy (PFS: 12.8 vs 2.2 months, P = 0.787; OS: 73.8 vs 56.5 months, P = 0.367). The ORRs and DCRs for all patients were 27.3% and 90.9%, respectively. The incidence of adverse events was 45.5% among the 11 thymoma patients, including immune-related myocarditis (36.4%), immune-related liver damage (18.2%), and myasthenia gravis (18.2%). In the whole cohort of patients, the rate of adverse events of grade 3 or higher was 36.4%. The rates of adverse events of grade 3 or 4 in B3-type and non-B3-type thymoma patients were 0% and 62.5%, respectively.
Immunotherapy elicited a response in thymoma patients; however, more attention should be paid to the immune-related adverse events.
免疫疗法已在胸腺癌患者中显示出疗效，但在胸腺瘤患者中确认这种疗效的数据不足。免疫疗法的毒性也有待确定。
根据客观缓解率（ORR）、疾病控制率（DCR）、无进展生存期（PFS）、总生存期（OS）和免疫治疗相关不良事件等一系列相关指标，分析了 11 例接受 PD-1 抑制剂治疗的胸腺瘤患者的免疫治疗疗效和安全性。
所有患者的 PFS 和 OS 率分别为 12.8 个月和 56.5 个月。单药治疗和联合治疗的疗效无差异（PFS：12.8 对 2.2 个月，P=0.787；OS：73.8 对 56.5 个月，P=0.367）。所有患者的 ORR 和 DCR 分别为 27.3%和 90.9%。11 例胸腺瘤患者的不良反应发生率为 45.5%，包括免疫相关性心肌炎（36.4%）、免疫相关性肝损伤（18.2%）和重症肌无力（18.2%）。在整个患者队列中，3 级或以上不良反应发生率为 36.4%。B3 型和非 B3 型胸腺瘤患者的 3 级或 4 级不良反应发生率分别为 0%和 62.5%。
免疫疗法在胸腺瘤患者中引发了反应，但应更加关注免疫相关的不良反应。
